Condition: Rectal Cancer · Sponsor: University of Nebraska
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
This description comes directly from the study's public registry record.
Jessi E Delaney, RN, BSN · 402-599-8711 · jessdelaney@unmc.edu
Samuel P Anderson, BS · 402-559-1250 · samuanderson@unmc.edu
Always discuss trial participation with your own doctor first.
| Markey Cancer Center | Lexington, Kentucky, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| UT Health San Antonio MD Anderson Cancer Center | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05254327